J Korean Pediatr Soc.
2000 Aug;43(8):1090-1097.
A Prospective Study on Ceftriaxone-associated Biliary Pseudolithiasis:
A Dose-related Comparison
Abstract
-
PURPOSE: Ceftriaxone, a parenteral third-generation cephalosporine, is widely used in the
treatment of various bacterial infections. It possesses high calcium-binding affinity,
forming complexes with calcium in bile salts to develop precipitate that mimics gallstone
on ultrasonography. Biliary pseudolithiasis resolves completely with cessation of therapy,
but several symptomatic patients have undergone cholesystectomy. We prospectively evaluated
the incidence, risk factors and dose- related comparison with ultrasonography.
METHODS
Between November 1998 and August 1999, 81 cases of inpatients on ceftriaxone
treatment in Dongguk University Pohang Hospital were enrolled for this study. They were
divided according to dose of ceftriaxone, high-dose and low-dose groups. Repeated sonography
was performed on 1, 3, 5 and 7 days after initiation of ceftriaxone treatrnent and then
weekly until pseudolithiasis were resolved.
RESULTS
Thirty-eight percent of the subjects acquired pseudolithiasis. Sonographic
abnormalities appeared from 1 to 10 days after ceftriaxone therapy and completely resolved
from 1 to 24 days after cessation of ceftriaxone therapy. The incidence of pseudolithiasis
was significantly higher in the high-dose group(P<0.001). In the high-dose group, fasting
over a day was a significant risk factor of pseudolithiasis(P<0.01). Sex, age, duration
of ceftriaxone therapy, laboratory findings, type of infection or chief complaint were not
significant risk factors for pseudolithiasis.
CONCLUSION
We suggest that abdominal ultrasonography should be considered in all children
who receive high dose ceftriaxone with fasting over a day. If pseudolithiasis was developed,
we can detect the most of resolution after 30 days of cessation of therapy.